Protalix BioTherapeutics (NYSE:PLX) Downgraded by StockNews.com to Buy

StockNews.com cut shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research report report published on Thursday morning.

Separately, HC Wainwright upped their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

Protalix BioTherapeutics Trading Up 4.9 %

PLX opened at $2.36 on Thursday. The firm has a market capitalization of $184.16 million, a PE ratio of -18.15 and a beta of 0.72. Protalix BioTherapeutics has a twelve month low of $0.82 and a twelve month high of $2.76. The firm’s 50-day moving average price is $2.39 and its 200 day moving average price is $1.74.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PLX. Renaissance Technologies LLC grew its holdings in shares of Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock valued at $2,102,000 after purchasing an additional 162,100 shares during the period. Northern Trust Corp grew its stake in shares of Protalix BioTherapeutics by 1,299.4% in the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company’s stock valued at $1,376,000 after buying an additional 679,451 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after buying an additional 33,969 shares during the last quarter. Millennium Management LLC raised its position in shares of Protalix BioTherapeutics by 3.8% during the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock valued at $729,000 after buying an additional 14,164 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock valued at $214,000 after acquiring an additional 67,664 shares during the last quarter. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.